RecruitingEarly Phase 1NCT07640555

Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

Sponsor

MODAG GmbH

Enrollment

13 participants

Start Date

May 13, 2026

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease Healthy Adult Multiple System Atrophy (MSA)

Summary

This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \[¹⁸F\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study. Each participant will receive a single intravenous injection of \[¹⁸F\]MODAG-009, followed by PET imaging using the investigational United Imaging NeuroEXPLORER (NX) camera.

Eligibility

Min Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called [¹⁸F]MODAG-009 PET imaging for people with healthy adult, multiple system atrophy (msa), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[¹⁸F]MODAG-009 PET imaging

Participants enrolled in the study will receive a single IV injection of \[¹⁸F\]MODAG-009 followed by dynamic PET imaging using the United Imaging NeuroEXPLORER (NX) brain PET scanner.